210 related articles for article (PubMed ID: 18303436)
41. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.
Masters GA; Hoffman PC; Hsieh A; Drinkard LC; Mick R; Samuels BL; Guaspari A; Golomb HM; Vokes EE
J Clin Oncol; 1997 Mar; 15(3):884-92. PubMed ID: 9060524
[TBL] [Abstract][Full Text] [Related]
42. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
43. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
Winton T; Livingston R; Johnson D; Rigas J; Johnston M; Butts C; Cormier Y; Goss G; Inculet R; Vallieres E; Fry W; Bethune D; Ayoub J; Ding K; Seymour L; Graham B; Tsao MS; Gandara D; Kesler K; Demmy T; Shepherd F; ;
N Engl J Med; 2005 Jun; 352(25):2589-97. PubMed ID: 15972865
[TBL] [Abstract][Full Text] [Related]
44. Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Scinto AF; Ferraresi V; Milella M; Tucci E; Santomaggio C; Pasquali-Lasagni R; Del Vecchio MR; Campioni N; Nardi M; Cognetti F
Br J Cancer; 1999 Nov; 81(6):1031-6. PubMed ID: 10576661
[TBL] [Abstract][Full Text] [Related]
45. Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Luo J; Wu FY; Li AW; Zheng D; Liu JM
Asian Pac J Cancer Prev; 2012; 13(9):4703-6. PubMed ID: 23167406
[TBL] [Abstract][Full Text] [Related]
46. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
48. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Vallejo C; Romero A; Perez J; Cuevas M; Lacava J; Sabatini C; Dominguez M; Rodriguez R; Barbieri M; Romero Acuña L; Romero Acuña J; Langhi M; Amato S; Salvadori M; Ortiz E; Machiavelli M; Leone B
Am J Clin Oncol; 1996 Dec; 19(6):584-8. PubMed ID: 8931677
[TBL] [Abstract][Full Text] [Related]
49. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
50. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
[TBL] [Abstract][Full Text] [Related]
51. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Efremidis A; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
J Clin Oncol; 1998 Apr; 16(4):1388-96. PubMed ID: 9552042
[TBL] [Abstract][Full Text] [Related]
52. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.
Kreuter M; Vansteenkiste J; Griesinger F; Hoffmann H; Dienemann H; De Leyn P; Thomas M
BMC Cancer; 2007 May; 7():77. PubMed ID: 17488518
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
54. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Planting AS; de Wit R; van der Burg ME; Stoter G; Verweij J
Ann Oncol; 1996 Dec; 7(10):1080-2. PubMed ID: 9037369
[TBL] [Abstract][Full Text] [Related]
56. Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
Hilbe W; Pall G; Kocher F; Pircher A; Zabernigg A; Schmid T; Schumacher M; Jamnig H; Fiegl M; Gächter A; Freund M; Kendler D; Manzl C; Zelger B; Popper H; Wöll E
PLoS One; 2015; 10(5):e0125364. PubMed ID: 26020783
[TBL] [Abstract][Full Text] [Related]
57. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H
Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.
Sonobe M; Okubo K; Teramukai S; Yanagihara K; Sato M; Sato T; Chen F; Sato K; Fujinaga T; Shoji T; Omasa M; Sakai H; Miyahara R; Bando T; Date H
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1199-206. PubMed ID: 25253046
[TBL] [Abstract][Full Text] [Related]
59. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Arriagada R; Bergman B; Dunant A; Le Chevalier T; Pignon JP; Vansteenkiste J;
N Engl J Med; 2004 Jan; 350(4):351-60. PubMed ID: 14736927
[TBL] [Abstract][Full Text] [Related]
60. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
